Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Sponsor

Institute Of Oncology Ljubljana

Slovenia Zaloska Cesta 2, 1000 Ljubljana, Slovenia

About the sponsor

The sponsor is involved in clinical research for colon cancer, with interest in perioperative management for patients undergoing colorectal surgery. The work reflects attention to postoperative recovery, pain control, and opioid-sparing analgesia.

  • Postoperative analgesic management
  • Immune response after surgery
  • Enhanced recovery in colorectal procedures

Clinical activity in this area is centered on improving the surgical course for patients treated for gastrointestinal malignancies.

About Specializations

Institute Of Oncology Ljubljana runs clinical trials in conditions such as Vascular malformation, Colon cancer, Breast cancer, Chemotherapy cardiotoxicity attenuation, among others.

Recruiting now

Ongoing trials

Clinical trials run by this sponsor – those enrolling participants first.

Condition
Country
City
Type of trial
Recruitment status
Quick filters

4 clinical trials

Vascular malformation

Recruiting

A study to evaluate the effectiveness of bleomycin sulfate for treating patients with low-flow vascular malformations using electrosclerotherapy.

Registered drugNo placebo
Countries:SloveniaSlovenia
  • Participants:18–64 years · 65+ years
  • Substances:Bleomycin Sulfate
  • Sponsor:Institute Of Oncology Ljubljana

Colon cancer

Recruiting

A study evaluating the effects of intravenous lidocaine on pain control and recovery after colon cancer surgery

Registered drug
Countries:SloveniaSlovenia
  • Participants:18–64 years · 65+ years
  • Substances:Sodium Chloride
  • Sponsor:Institute Of Oncology Ljubljana

Breast cancer+1

Not yet recruiting

Dapagliflozin for prevention of heart damage in women with breast cancer receiving anthracycline chemotherapy

Registered drug
Countries:SloveniaSlovenia
  • Participants:18–64 years · 65+ years
  • Substances:Dapagliflozin
  • Sponsor:Institute Of Oncology Ljubljana

Renal cell carcinoma

Not yet recruiting

Efficacy of pembrolizumab drug combination in advanced renal cell carcinoma: early prediction using serum KIM-1 and MAdCAM-1

Registered drugNo placebo
Countries:SloveniaSlovenia
  • Participants:18–64 years · 65+ years
  • Substances:Cabozantinib
  • Sponsor:Institute Of Oncology Ljubljana

Are you running a clinical trial?

Increase visibility for your trials and help patients find your site through our platform.

Join now →
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.